Abstract
MET amplification (METamp) is a mechanism of acquired resistance to EGFR TKIs, occurring in ∼15% of patients (pts) who progress on 1st-line (1L) osimertinib therapy. Combination with a MET TKI may overcome MET-related osimertinib resistance.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
